Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples